ValuEngine downgraded shares of Female Health Company (The) (NASDAQ:FHCO) from a hold rating to a sell rating in a research note released on Friday.

Other equities research analysts also recently issued reports about the company. HC Wainwright set a $5.00 target price on Female Health Company (The) and gave the stock a buy rating in a report on Wednesday, July 26th. Rodman & Renshaw initiated coverage on Female Health Company (The) in a report on Wednesday, July 26th. They issued a buy rating and a $5.00 target price for the company.

Shares of Female Health Company (FHCO) opened at 1.20 on Friday. The stock has a 50 day moving average price of $1.14 and a 200-day moving average price of $1.07. Female Health Company has a 52 week low of $0.72 and a 52 week high of $1.65. The company’s market capitalization is $37.61 million.

Female Health Company (The) (NASDAQ:FHCO) last issued its earnings results on Tuesday, May 9th. The company reported ($0.06) earnings per share for the quarter. The business had revenue of $2.41 million during the quarter. Female Health Company (The) had a negative return on equity of 12.51% and a negative net margin of 29.27%. Equities research analysts expect that Female Health Company will post $0.15 EPS for the current year.

WARNING: This piece of content was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at

In other Female Health Company (The) news, Director Harry Fisch bought 24,750 shares of the stock in a transaction on Monday, May 22nd. The stock was acquired at an average cost of $1.02 per share, for a total transaction of $25,245.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mitchell Shuster Steiner bought 55,000 shares of the stock in a transaction on Monday, June 12th. The stock was acquired at an average price of $1.27 per share, with a total value of $69,850.00. Following the completion of the acquisition, the insider now owns 645,502 shares of the company’s stock, valued at approximately $819,787.54. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 230,569 shares of company stock valued at $266,867. 10.90% of the stock is currently owned by corporate insiders.

About Female Health Company (The)

The Female Health Company is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Female Health Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.